Jazz Pharmaceuticals JAZZ Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's total equity?
- Jazz Pharmaceuticals (JAZZ) reported total equity of $4.53B in Q1 2026.
- How has Jazz Pharmaceuticals's total equity changed year-over-year?
- Jazz Pharmaceuticals's total equity increased by 8.6% year-over-year, from $4.17B to $4.53B.
- What is the long-term trend for Jazz Pharmaceuticals's total equity?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's total equity has grown at a 3.4% compound annual growth rate (CAGR), from $3.66B to $4.32B.
- What does total equity mean?
- The total value of the company belonging to shareholders, calculated as assets minus liabilities.
- How do you interpret total equity?
- Growth in equity generally signals value creation, while a decline may indicate losses, share buybacks, or dividend payments.
- How does total equity compare across companies?
- Standard across all companies; essential for calculating Return on Equity (ROE).